Short Course: Notes on HIV Drugs in Development

December 2002

This article is part of The Body PRO's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

Tipping the Scales at 500 mg -- Tipranavir!

Boehringer Ingelheim has announced that they have finally settled on a dosage for their protease inhibitor, tipranavir. Now, larger Phase III clinical trials of the drug can begin. A recently completed Phase II study had compared three different dose combinations of tipranavir plus ritonavir given twice daily. A dosage of 500 mg tipranavir plus 200 mg ritonavir was chosen as providing the best balance of adequate viral suppression with the fewest side effects. The ritonavir acts to keep blood levels of tipranavir higher, longer, by slowing its metabolism through the liver.

The Phase II study was conducted in people with extensive experience using multiple drugs in all classes of antiretroviral therapy. Since tipranavir may be able to suppress multiple-PI resistant and wild type virus with about equal efficacy, it represents an urgently needed therapy for people who've run out of treatment options. Even though primary resistance to tipranavir itself seems to be slow to develop, people who still have an array of treatment choices probably won't choose tipranavir. Besides being a twice-a-day product, ritonavir boosted tipranavir is likely to raise blood lipid levels and cause drug interactions and tolerability problems. Unfortunately, these are factors that will also limit its use among some people who will desperately need it.

Having settled on a dose, Boehringer is now set to start up a pair of large Phase III trials. One study (RESIST 1) will be a 24-week trial in sites throughout North and South America, and Australia. A 16-week trial (RESIST 2) will be conducted exclusively in Europe. The time to approval of tipranavir will depend on how quickly the Phase III studies are enrolled, how much time the company needs to pull its data together for the FDA, and how long the FDA needs to review the application. Mid 2004 would be an optimistic guess.

As the Phase III trials get going, and with the approval of T-20 (Fuzeon) expected in March, it becomes urgent to finalize the details of a tipranavir expanded access program for people with no other treatment options. We know that T-20 has the best shot at working when it is accompanied by at least one other drug active against an individual's viral strain, and for many, tipranavir is the best candidate on the horizon. With access to T-20, tipranavir and atazanavir opening up in the next six months, things might start looking brighter for the growing number of people who critically need an effective third, fourth or fifth-line regimen.


Back to the GMHC Treatment Issues December 2002 contents page.

This article was provided by Gay Men's Health Crisis. It is a part of the publication GMHC Treatment Issues. Visit GMHC's website to find out more about their activities, publications and services.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.